Holen Sie sich die Stockscreener-App
5.59
7.50%
0.39
Handel nachbörslich:
5.57
-0.02
-0.36%
Cellectar Biosciences Inc Aktie (CLRB) Neueste Nachrichten
What drives Cellectar Biosciences Inc. stock priceBreakneck growth rates - Autocar Professional
Cellectar Biosciences Inc. Stock Analysis and ForecastSpectacular growth rates - jammulinksnews.com
What analysts say about Cellectar Biosciences Inc. stockExceptional trading performance - Autocar Professional
Is Cellectar Biosciences Inc. a good long term investmentConsistently exceptional gains - Autocar Professional
Cellectar’s Cancer Therapy Hopes Face A Cash Crunch - Finimize
What makes Cellectar Biosciences Inc. stock price move sharplySafety First Trading Signals - Newser
All You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy - MSN
How Cellectar Biosciences Inc. stock performs during market volatilityRapid Gain Targets - Newser
Why Cellectar Biosciences Inc. stock attracts strong analyst attentionFree Stock Market Return Analysis - Newser
Waldenstrom Macroglobulinemia Market Sees Surging Demand Across the 7MM Amid BTK Inhibitor Advancements | DelveInsight - GlobeNewswire Inc.
Sequoia Financial Advisors LLC Purchases 188,760 Shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Cellectar Biosciences shares rise 3.59% premarket after closing $6.9 million public offering. - AInvest
Cellectar Biosciences Announces Closing of $6.9 Million - GlobeNewswire
Cellectar Biosciences Closes $6.9 Million Public Offering - MarketScreener
Cellectar Biosciences, Inc. Completes $6.9 Million Public Offering to Advance Cancer Treatment Development - Quiver Quantitative
Cellectar Secures $6.9M Funding: Healthcare Funds Back New Breast Cancer Drug Development - Stock Titan
Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering | CLRB Stock News - GuruFocus
Cellectar Biosciences prices $6 million public offering - Investing.com
Cellectar Biosciences, Inc. Announces Pricing of Underwritten Public Offering for Approximately $6 Million - Quiver Quantitative
Cellectar Biosciences prices $6 million public offering By Investing.com - Investing.com UK
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch - The Globe and Mail
Cellectar Biosciences (NASDAQ:CLRB) Rating Increased to Sell at Wall Street Zen - Defense World
Cellectar Biosciences, Inc. and Nusano Enter into Multi-Isotope Supply Agreement - MarketScreener
Cellectar Biosciences provides update on clinical programs and preclinical data - Investing.com
Cellectar and Nusano sign multi-year radioisotope supply agreement By Investing.com - Investing.com India
Cellectar Biosciences enacts one-for-thirty reverse stock split on Nasdaq - Investing.com
Cellectar Biosciences (CLRB) Submits Study Protocol to FDA for P - GuruFocus
Cellectar Biosciences Trading Halted: News Pending - AInvest
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split - The Manila Times
Cellectar Biosciences announces one-for-thirty reverse stock split - MarketScreener
Cellectar Biosciences (CLRB) Announces One-for-Thirty Reverse St - GuruFocus
Cellectar Biosciences announces 1:30 reverse stock split - Investing.com
Cellectar Biosciences (CLRB) Announces Reverse Stock Split | CLR - GuruFocus
Cellectar Biosciences Reports 1-for-30 Reverse Stock Split, Effective June 24 - marketscreener.com
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split | CLRB Stock News - GuruFocus
Cellectar Biosciences, Inc. Announces One-for-Thirty Reverse Stock Split Effective June 24, 2025 - Nasdaq
Roth Capital Issues Positive Estimate for CLRB Earnings - Defense World
Cellectar Biosciences Approves Reverse Stock Split Proposal - TipRanks
4.91%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):